Sorry, no posts matched your criteria.
Subscribe to BioTuesdays Weekly Email
-
Biotuesdays.com RSS FEEDS
Search BioTuesdays
Creative Commons License
-
RECENT POSTS
Like us on Facebook!
Twitter Updates
- In Conversation with Matt Dolan http://t.co/pjUa0dV0 about 11 hours ago from Google
- In Conversation with Matt Dolan: Matt Dolan As a senior research analyst focused on medical technology: ... http://t.co/TK39tktr about 12 hours ago from twitterfeed
- Pluristem to expand R&D of radiation exposure treatment http://t.co/NXiP0gwL about 12 hours ago from Google
- Rodman ups Alnylam price target to $19 http://t.co/Cfdbu444 about 1 day ago from Google
- Rodman ups Alnylam price target to $19: Rodman & Renshaw has raised its year-end price target for “marke... http://t.co/55AQr8tl about 1 day ago from twitterfeed
-
Tags
Alnylam Pharmaceuticals AMF amorfix BioSante Pharmaceuticals biotech Canaccord Genuity Cipher Pharmaceuticals ColonSentry D. Medical Industries David Martin diabetes Doug Loe Dr. Robert Foster Dry Eye Disease Efri Argaman Elias Vamvakas FDA Gailina Liew GEN GeneNews hypoactive sexual desire disorder Immunovaccine Isotechnika Pharma Labopharm LibiGel Lymphoseek NASDAQ NASDAQ:BPAX NASDAQ:TEAR Neoprobe Paladin Labs Pfizer RBC Capital Markets Rodman & Renshaw Roth Capital Partners Stellar Pharmaceuticals Stephen Simes TearLab Theratechnologies TSX TSX-V TSX:PLB Uracyst Versant Partners voclosporin
WP Cumulus Flash tag cloud by Roy Tanck and Luke Morton requires Flash Player 9 or better.
Listen to BioTuesdays Categories
Archives
Links
